ICM
ABUS icon

Irenic Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Irenic Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-59,853
Closed -$288K – 47
2025
Q4 		$288K Buy
+59,853
New +$269K 0.02% 43

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Irenic Capital Management's ABUS Position: Q1 2026 in Review

Irenic Capital Management sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 59,853 shares — an estimated $288K sold.

Irenic Capital Management first reported a position in ABUS in Q4 2025 and held it in 1 quarter. The position peaked at $288K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Irenic Capital Management reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Irenic Capital Management sold 59,853 Arbutus Biopharma shares in Q1 2026, an estimated $288K.
  • Irenic Capital Management first reported a position in Arbutus Biopharma in Q4 2025 and held it in 1 quarter.
  • Irenic Capital Management's Arbutus Biopharma position peaked at $288K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Irenic Capital Management's 13F filing for Q1 2026, filed 18 May 2026.